Document Detail

Ondansetron--the first of a new class of antiemetic agents.
MedLine Citation:
PMID:  1829668     Owner:  NLM     Status:  MEDLINE    
The chemistry, pharmacokinetics, adverse effects, stability, compatibility, and dosage of ondansetron hydrochloride are described, and clinical studies of the use of ondansetron for the prophylaxis of nausea and vomiting induced by antineoplastic therapy are reviewed. Ondansetron hydrochloride is a specific antagonist of serotonin type 3 (5-HT3) receptors, both in the chemoreceptor trigger zone and in the GI tract. Peak plasma concentrations of ondansetron occur approximately one hour after an oral dose and 6 to 20 minutes after an i.v. dose. The mean elimination half-life is approximately 3.5 hours in healthy volunteers, but it is extended in elderly patients (mean of 7.9 hours). In clinical trials, ondansetron has been shown to provide excellent control of nausea and vomiting in patients treated with cisplatin. Comparisons of ondansetron with metoclopramide in patients treated with various types of chemotherapy have shown better response rates with ondansetron. Ondansetron has also been shown to be effective in controlling nausea and vomiting in patients receiving cyclophosphamide with an anthracycline and in patients receiving combination therapy with cyclophosphamide, methotrexate, and fluorouracil. Adverse effects appear to be mild and include headache, constipation, diarrhea and transient abnormalities in liver function tests. The dose of ondansetron (as the hydrochloride salt) for the prophylaxis of chemotherapy-induced nausea and vomiting in adults is 0.15 mg/kg i.v. every four hours for three doses, beginning 30 minutes before antineoplastic therapy. The efficacy of ondansetron is comparable to that of metoclopramide, and the adverse-effect profile is much less problematic. The cost of ondansetron is much higher than that of metoclopramide; thus its use should be limited to patients at high risk for metoclopramide-induced adverse effects and patients in whom metoclopramide is ineffective.
B J Chaffee; R M Tankanow
Related Documents :
8102428 - Dexamethasone therapy for bacterial meningitis in children. swiss meningitis study group.
2726308 - The effect of dexamethasone on chronic pulmonary oxygen toxicity in infant mice.
2663518 - Concentrations of ceftazidime, tobramycin and ampicillin in the cerebrospinal fluid of ...
9081358 - A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous do...
422308 - Pharmacokinetics of carbamazepine in the neonate and in the child.
20448848 - Acute toxicity study and antipyretic effect of the brown alga turbinaria conoides (j. a...
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Review    
Journal Detail:
Title:  Clinical pharmacy     Volume:  10     ISSN:  0278-2677     ISO Abbreviation:  Clin Pharm     Publication Date:  1991 Jun 
Date Detail:
Created Date:  1991-08-15     Completed Date:  1991-08-15     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8207437     Medline TA:  Clin Pharm     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  430-46     Citation Subset:  IM    
Department of Pharmacy Services, University of Michigan Medical Center, Ann Arbor 48109.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antiemetics* / adverse effects,  pharmacokinetics,  therapeutic use
Antineoplastic Agents / adverse effects
Imidazoles* / adverse effects,  pharmacokinetics,  therapeutic use
Multicenter Studies as Topic
Nausea / chemically induced,  prevention & control*
Vomiting / chemically induced,  prevention & control*
Reg. No./Substance:
0/Antiemetics; 0/Antineoplastic Agents; 0/Imidazoles; 99614-02-5/Ondansetron

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effects of V2 receptor activity on the pressor response to vasopressin in the rat.
Next Document:  Negligence of the physician's duty to care during "therapeutic local anesthesia"